

**CAR T-Cell Therapy Market by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), Region, Competitive Landscape - Global Forecast to 2031**

Market Report | 2026-02-16 | 320 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The global CAR T-cell therapy market is projected to reach USD 13.78 billion in 2031 from USD 7.24 billion in 2026, at a CAGR of 13.7%. Market growth is primarily driven by rising global cancer prevalence. Technological advancements in CAR T-cell therapies and rising investment and funding for therapy development are likely to propel market growth. However, adverse effects associated with CAR T-cell therapy and high treatment costs are among the major factors expected to restrain market growth during the forecast period.

<https://mnmimg.marketsandmarkets.com/Images/car-t-cell-therapy-market-img-overview.webp>

"The Yescarta product segment accounted for the largest share by product in the CAR T-cell therapy market in 2025." Based on product, the CAR T-cell therapy market is broadly segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel), and other products.

The Yescarta segment held the largest market share in 2025. Market growth is driven by high response rates and durable remissions with Yescarta in treating relapsed/refractory cancers, leading to increased therapy adoption.

?

"The hospitals segment accounted for the largest share by end user segment in the CAR T-cell therapy market in 2025." Based on end users, the global CAR T-cell therapy market is segmented into hospitals, long-term care facilities, and specialty

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

centers. In 2025, the hospitals segment emerged as the primary growth driver in the global CAR T-cell therapy market, with the highest CAGR during the forecast period.

Hospitals are incorporating CAR T-cell therapies into their standard oncology treatment protocols. This trend is boosting demand for CAR T-cell therapies as more hospitals embrace them. Furthermore, hospitals play a key role in facilitating clinical trials for CAR T-cell therapies. By actively participating in research initiatives and collaborating with pharmaceutical companies and hospitals, the evidence base expands, and regulatory approvals accelerate, which, in turn, stimulate market growth.

"Asia Pacific is projected to grow at the highest CAGR in the CAR T-cell therapy market from 2026 to 2031."

The CAR T-cell therapy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, Asia Pacific is estimated to grow at the highest CAGR. The supportive regulatory frameworks, rich CAR T-cell therapy product pipeline, and expedited approval processes facilitate quicker market entry for innovative therapies, driving growth in Asia Pacific. In addition, increased collaborations among hospitals, universities, and industries in China are expected to drive robust market growth. The rapid increase in clinical trials evaluating the safety and effectiveness of CAR T-cell therapy across diverse cancer types in China also signals significant advancements. These studies have demonstrated encouraging results in treating leukemia, lymphoma, and solid tumors, with specific patient cohorts showing substantial rates of complete remission and sustained responses. This trend highlights Asia Pacific's progress in developing and validating CAR T-cell therapies, positioning the region as a key player in advancing oncology therapeutic outcomes.

The primary interviews conducted for this report can be categorized as follows:

- By Company Type: Tier 1- 40%, Tier 2- 30%, and Tier 3- 30%
- By Designation: Directors- 20%, Managers- 10%, and Others - 70%,
- By Region: North America -35%, Europe -25%, Asia Pacific -25%, Latin America -10%, and Middle East -5%.

List of Companies Profiled in the Report:

- Bristol-Myers Squibb Company (US)
- Gilead Sciences Inc. (US)
- Novartis AG (Switzerland)
- Johnson & Johnson (US)
- CARsgen Therapeutics Holdings Limited (China)
- IASO Biotherapeutics (China)
- W (Cayman) Therapeutics Co., Ltd (China)
- ImmunoAct (India)
- CRISPR Therapeutics (Switzerland)
- Autolus Therapeutics (UK)
- Allogene Therapeutics (US)
- Cartesian Therapeutics Inc. (US)
- Guangzhou Bio-gene Technology Co., Ltd (China)
- Wugen (US)

Research Coverage:

This research report categorizes the CAR T-cell therapy market by product (YESCARTA, KYMRIA, CARVYKTI, ABECMA, TECARTUS, BREYANZI, Other products); by target: CD19, BCMA, other targets; by indication: Multiple myeloma, B-cell lymphoma, Acute lymphoblastic leukemia, Other indications; by demographics: adult, pediatric; by End User: Hospitals, Specialty centers, Long-term care facilities, and by region: North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the CAR T-cell therapy market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, product portfolios, key strategies, such as product launches, collaborations,

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

partnerships, expansions, agreements, and recent developments in the CAR T-cell therapy market. This report provides a competitive analysis of top players and emerging startups in the CAR T-cell therapy market ecosystem.

**Key Benefits of Buying the Report:**

The report will help market leaders/new entrants by providing the closest approximations of revenue for the overall CAR T-cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (Technological advancements in CAR T-cell therapies, Label expansions along with strong efficacy signals in hematologic cancers, Growing investments in the development of therapies), restraints (High cost and reimbursement challenges), opportunities (Expanding beyond hematologic malignancies into solid tumors and new disease areas, Focus shift on allogeneic CAR-T and CAR-NK), and challenges (Long-term safety surveillance and evolving labeling requirements) are influencing the growth of CAR T-cell therapy market.

-□Product Development/Innovation: Detailed insights on newly launched products of the CAR T-cell therapy market.

-□Market Development: Comprehensive information about lucrative markets - the report analyses the CAR T-cell therapy market across varied regions.

-□Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CAR T-cell therapy market.

-□Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Johnson & Johnson (US), JW (Cayman) Therapeutics Co. Ltd (China), ImmunoAct (India), among others in the CAR T-cell therapy market.

## **Table of Contents:**

1	INTRODUCTION	31
1.1	STUDY OBJECTIVES	31
1.2	MARKET DEFINITION	31
1.3	STUDY SCOPE	32
1.3.1	MARKET SEGMENTATION & REGIONAL SCOPE	32
1.3.2	INCLUSIONS & EXCLUSIONS	33
1.3.3	YEARS CONSIDERED	34
1.3.4	CURRENCY CONSIDERED	34
1.4	STAKEHOLDERS	34
1.5	SUMMARY OF CHANGES	35
2	EXECUTIVE SUMMARY	36
2.1	KEY INSIGHTS & MARKET HIGHLIGHTS	36
2.2	KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS	37
2.3	DISRUPTIVE TRENDS SHAPING MARKET	38
2.4	HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS	39
2.5	SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST	40
3	PREMIUM INSIGHTS	41
3.1	CAR T-CELL THERAPY MARKET OVERVIEW	41
3.2	NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC AND COUNTRY, 2025	42
3.3	CAR T-CELL THERAPY MARKET: GEOGRAPHIC SNAPSHOT	43
4	MARKET OVERVIEW	44
4.1	INTRODUCTION	44

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4.2	MARKET DYNAMICS	44
4.2.1	DRIVERS	45
4.2.1.1	Technological advancements in CAR T-cell therapies	45
4.2.1.2	Label expansions and strong efficacy signals in hematologic cancers	45
4.2.1.3	Growing investment in CAR T-cell therapy development	45
4.2.2	RESTRAINTS	46
4.2.2.1	High cost and reimbursement challenges for CAR T-cell therapy	46
4.2.3	OPPORTUNITIES	47
4.2.3.1	Expanding beyond hematologic malignancies into solid tumors and new disease areas	47
4.2.3.2	Focus shift on allogeneic CAR-T and CAR-NK	48
4.2.3.3	Growing collaborations among biopharmaceutical companies, academic institutions, and research organizations	49
?		
4.2.4	CHALLENGES	51
4.2.4.1	Long-term safety surveillance and evolving labeling requirements	51
4.3	UNMET NEEDS & WHITE SPACES	51
4.4	INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES	51
4.5	STRATEGIC MOVES BY TIER-1/2/3 PLAYERS	52
4.6	PIPELINE ANALYSIS	52
5	INDUSTRY TRENDS	55
5.1	PORTER'S FIVE FORCES ANALYSIS	55
5.1.1	THREAT OF NEW ENTRANTS	56
5.1.2	THREAT OF SUBSTITUTES	56
5.1.3	BARGAINING POWER OF BUYERS	56
5.1.4	BARGAINING POWER OF SUPPLIERS	57
5.1.5	INTENSITY OF COMPETITIVE RIVALRY	57
5.2	MACROECONOMIC OUTLOOK	57
5.2.1	INTRODUCTION	57
5.2.2	GDP TRENDS AND FORECASTS	58
5.2.3	TRENDS IN GLOBAL CAR-T-CELL THERAPY MARKET	58
5.3	VALUE CHAIN ANALYSIS	58
5.4	ECOSYSTEM ANALYSIS	60
5.4.1	ROLE IN ECOSYSTEM	61
5.5	PRICING ANALYSIS	62
5.5.1	AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS, BY TYPE, 2025	62
5.5.2	AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS, BY KEY PLAYER, 2025	63
5.5.3	AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS, BY REGION, 2025	64
5.6	KEY CONFERENCES & EVENTS, 2026-2027	64
5.7	TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS	65
5.8	INVESTMENT/FUNDING SCENARIO	66
5.9	IMPACT OF 2025 US TARIFF ON CAR T-CELL THERAPY MARKET	67
5.9.1	KEY TARIFF RATES	67
5.9.2	PRICE IMPACT ANALYSIS	68
5.9.3	IMPACT ON COUNTRY/REGION	68
5.9.3.1	North America	68

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.9.3.1.1	US	68
5.9.3.2	Europe	69
5.9.3.3	Asia Pacific	69
5.9.4	IMPACT ON END-USE INDUSTRIES	70
5.9.4.1	Hospitals	70
5.9.4.2	Specialty oncology centers	70
5.9.4.3	Long-term care facilities	71
6	TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS	72
6.1	TECHNOLOGY ANALYSIS	72
6.1.1	KEY TECHNOLOGIES	72
6.1.1.1	Car design and optimization	72
6.1.1.2	Viral vector technology	72
6.1.1.3	Cell culture and expansion techniques	73
6.1.2	COMPLEMENTARY TECHNOLOGIES	73
6.1.2.1	Gene editing technology (CRISPR-CAS9-based genome editing)	73
6.1.3	ADJACENT TECHNOLOGIES	74
6.1.3.1	Monitoring and imaging technologies	74
6.2	TECHNOLOGY/PRODUCT ROADMAP	75
6.3	FUTURE APPLICATIONS	75
6.4	IMPACT OF AI/GEN AI ON CAR T-CELL THERAPY MARKET	75
7	SUSTAINABILITY AND REGULATORY LANDSCAPE	77
7.1	REGIONAL REGULATIONS AND COMPLIANCE	77
7.1.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	77
7.1.2	REGULATORY FRAMEWORK	79
7.1.3	INDUSTRY STANDARDS	81
7.2	SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES	81
7.3	CERTIFICATIONS, LABELING, AND ECO-STANDARDS	82
7.4	REIMBURSEMENT SCENARIO	83
7.5	COMBINATION THERAPIES	84
8	CUSTOMER LANDSCAPE & BUYER BEHAVIOR	86
8.1	DECISION-MAKING PROCESS	86
8.2	BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA	86
8.2.1	KEY STAKEHOLDERS IN BUYING PROCESS	86
8.2.2	KEY BUYING CRITERIA, BY END USER	87
8.3	ADOPTION BARRIERS & INTERNAL CHALLENGES	88
8.4	UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES	89
8.5	MARKET PROFITABILITY	89
9	CAR T-CELL THERAPY MARKET, BY PRODUCT	90
9.1	INTRODUCTION	91
9.2	ABECMA	92
9.2.1	FOCUS ON INCREASED RESEARCH ACTIVITIES FOR INDICATION EXPANSIONS TO DRIVE MARKET	92
9.3	BREYANZI	96
9.3.1	NEED FOR TREATMENT OF MULTIPLE INDICATIONS TO PROPEL MARKET GROWTH	96
9.4	CARVYKTI	100
9.4.1	GLOBAL REACH AND SIGNIFICANT REVENUE GROWTH TO SUPPORT MARKET	100

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.5 YESCARTA 104
- 9.5.1 FOCUS ON REGULATORY APPROVALS ACROSS MAJOR REGIONS TO BOOST MARKET GROWTH 104
- 9.6 TECARTUS 107
- 9.6.1 EFFORTS TO SECURE REIMBURSEMENT AND IMPROVE MARKET ACCESS FACILITATE PATIENT TO AID MARKET ADOPTION 107
- 9.7 KYMRIA 110
- 9.7.1 APPROVAL FOR PEDIATRIC USE TO AUGMENT MARKET GROWTH 110
- 9.8 OTHER PRODUCTS 113
- 10 CAR T-CELL THERAPY MARKET, BY TARGET 117
- 10.1 INTRODUCTION 118
- 10.2 CD19 118
- 10.2.1 RISING INDICATION EXPANSIONS AND NEW APPROVALS TO DRIVE MARKET 118
- 10.3 BCMA 122
- 10.3.1 GROWING PIPELINE PRODUCTS TO PROPEL MARKET GROWTH 122
- 10.4 CD19/20 126
- 10.4.1 DUAL TARGETING TO OFFER COMPETITIVE ADVANTAGE IN ANTIGEN ESCAPE AND TUMOR HETEROGENEITY ISSUES 126
- 10.5 CD7 129
- 10.5.1 ALLOGENEIC CELL SOURCE OF CD7 THERAPIES IN DEVELOPMENT TO SUPPORT GROWTH 129
- 10.6 OTHER TARGETS 132
- 11 CAR T-CELL THERAPY MARKET, BY INDICATION 136
- 11.1 INTRODUCTION 137
- 11.2 B-CELL LYMPHOMA (BCL) 137
- 11.2.1 RISING PREVALENCE OF B-CELL LYMPHOMAS TO PROPEL MARKET GROWTH 137
- 11.3 MULTIPLE MYELOMA 141
- 11.3.1 GROWING PRODUCT REVENUE AND RISING GLOBAL INCIDENCE OF MYELOMA TO DRIVE MARKET 141
- 11.4 ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 144
- 11.4.1 EXPANDING R&D PIPELINE TO AUGMENT MARKET GROWTH 144
- 11.5 OTHER INDICATIONS 148
- 12 CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC 152
- 12.1 INTRODUCTION 153
- 12.2 ADULTS 153
- 12.2.1 GROWING PREVALENCE OF HEMATOLOGIC CANCERS TO DRIVE MARKET 153
- 12.3 PEDIATRIC 156
- 12.3.1 HIGH UNMET NEEDS TO LIMIT SEGMENT GROWTH 156
- 13 CAR T-CELL THERAPY MARKET, BY END USER 160
- 13.1 INTRODUCTION 161
- 13.2 HOSPITALS 161
- 13.2.1 GROWING NEED FOR STANDARD ONCOLOGY TREATMENT PROTOCOLS TO DRIVE MARKET 161
- 13.3 SPECIALTY CENTRES 165
- 13.3.1 NEED FOR OPTIMAL PATIENT CARE AND SPECIALIZED TREATMENT OPTIONS TO SPUR MARKET GROWTH 165
- 13.4 LONG-TERM CARE FACILITIES 168
- 13.4.1 INCREASING INCIDENCE OF CHRONIC DISORDERS AMONG GERIATRIC POPULATION TO PROPEL MARKET GROWTH 168
- 14 CAR T-CELL THERAPY MARKET, BY REGION 172
- 14.1 INTRODUCTION 173
- 14.2 NORTH AMERICA 173
- 14.2.1 US 177
- 14.2.1.1 US to dominate CAR T-cell therapy market during study period 177

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.2.2 CANADA 179
  - 14.2.2.1 Regulatory approvals and government initiatives for regenerative medicine research to drive market 179
- 14.3 EUROPE 181
  - 14.3.1 GERMANY 183
    - 14.3.1.1 Key product approvals and focus on clinical research to aid market growth 183
  - 14.3.2 UK 185
    - 14.3.2.1 Technological advancements in automation and presence of robust research infrastructure to spur market growth 185
  - 14.3.3 FRANCE 187
    - 14.3.3.1 Growing focus on cell & gene therapy initiatives to boost market growth 187
  - 14.3.4 ITALY 189
    - 14.3.4.1 Growth in biotech sector to augment market growth 189
  - 14.3.5 SPAIN 191
    - 14.3.5.1 Rising focus on cell therapies and growing focus on stringent regulations to augment market growth 191
  - 14.3.6 REST OF EUROPE 193
- 14.4 ASIA PACIFIC 196
  - 14.4.1 CHINA 199
    - 14.4.1.1 Rising number of CAR T-cell clinical trials to fuel market growth 199
  - 14.4.2 JAPAN 202
    - 14.4.2.1 Increasing number of product approvals and rising geriatric population to propel market growth 202
  - 14.4.3 INDIA 204
    - 14.4.3.1 Growing focus on product commercialization and rising cancer incidence to boost market demand 204
  - 14.4.4 AUSTRALIA 206
    - 14.4.4.1 Robust infrastructure for clinical trials and well-developed healthcare sector to aid market growth 206
  - 14.4.5 SOUTH KOREA 209
    - 14.4.5.1 Growth in biopharmaceutical industry to facilitate market growth 209
  - 14.4.6 REST OF ASIA PACIFIC 211
- 14.5 LATIN AMERICA 213
  - 14.5.1 BRAZIL 216
    - 14.5.1.1 Product approvals and high healthcare expenditure to support market growth 216
  - 14.5.2 REST OF LATIN AMERICA 218
- 14.6 MIDDLE EAST 221
  - 14.6.1 GCC COUNTRIES 223
    - 14.6.2 KINGDOM OF SAUDI ARABIA 226
      - 14.6.2.1 Increased number of product approvals and high healthcare expenditure to boost market growth 226
    - 14.6.3 UAE 228
      - 14.6.3.1 UAE market growth to be driven by localized manufacturing, expanded clinical applications, and strategic collaborations 228
  - 14.6.4 REST OF MIDDLE EAST 230
- 14.7 AFRICA 232
  - 14.7.1 SIGNIFICANT BURDEN OF HEMATOLOGIC MALIGNANCIES AND INFECTIOUS DISEASES TO PROPEL MARKET GROWTH 232
- 15 COMPETITIVE LANDSCAPE 235
  - 15.1 INTRODUCTION 235
  - 15.2 KEY PLAYER STRATEGY/RIGHT TO WIN 235
    - 15.2.1 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY PLAYERS IN CAR T-CELL THERAPY MARKET 235
  - 15.3 REVENUE ANALYSIS, 2023-2025 237
  - 15.4 MARKET SHARE ANALYSIS, 2025 237

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025	240
15.5.1	STARS	240
15.5.2	EMERGING LEADERS	240
15.5.3	PERVASIVE PLAYERS	240
15.5.4	PARTICIPANTS	240
15.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2025	242
15.5.5.1	Company footprint	242
15.5.5.2	Region footprint	243
15.5.5.3	Product footprint	244
15.5.5.4	Target footprint	245
15.5.5.5	Indication footprint	246
15.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025	246
15.6.1	PROGRESSIVE COMPANIES	246
15.6.2	RESPONSIVE COMPANIES	246
15.6.3	DYNAMIC COMPANIES	246
15.6.4	STARTING BLOCKS	247
15.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025	248
15.6.5.1	Detailed list of key startups/SMEs	248
15.6.5.2	Competitive benchmarking of startups/SMEs	249
15.7	COMPANY VALUATION & FINANCIAL METRICS	250
15.7.1	FINANCIAL METRICS	250
15.7.2	COMPANY VALUATION	250
15.8	BRAND/PRODUCT COMPARISON	251
15.9	COMPETITIVE SCENARIO	252
15.9.1	PRODUCT APPROVALS	252
15.9.2	DEALS	253
15.9.3	EXPANSIONS	253
15.9.4	OTHER DEVELOPMENTS	254
16	COMPANY PROFILES	255
16.1	KEY PLAYERS	255
16.1.1	JOHNSON & JOHNSON	255
16.1.1.1	Business overview	255
16.1.1.2	Products offered	256
16.1.1.3	Recent developments	257
16.1.1.3.1	Product approvals	257
16.1.1.3.2	Deals	257
16.1.1.4	MnM view	258
16.1.1.4.1	Key strengths	258
16.1.1.4.2	Strategic choices	258
16.1.1.4.3	Weaknesses & competitive threats	258
16.1.2	GILEAD SCIENCES, INC.	259
16.1.2.1	Business overview	259
16.1.2.2	Products offered	260
16.1.2.3	Recent developments	261
16.1.2.3.1	Product approvals	261
16.1.2.3.2	Deals	262
16.1.2.3.3	Other developments	262

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.1.2.4 MnM view 263
  - 16.1.2.4.1 Key strengths 263
  - 16.1.2.4.2 Strategic choices 263
  - 16.1.2.4.3 Weaknesses & competitive threats 263
- 16.1.3 BRISTOL-MYERS SQUIBB COMPANY 264
  - 16.1.3.1 Business overview 264
  - 16.1.3.2 Products offered 266
  - 16.1.3.3 Recent developments 266
    - 16.1.3.3.1 Product approvals 266
    - 16.1.3.3.2 Deals 268
  - 16.1.3.4 MnM view 268
    - 16.1.3.4.1 Key strengths 268
    - 16.1.3.4.2 Strategic choices 268
    - 16.1.3.4.3 Weaknesses & competitive threats 268
- 16.1.4 NOVARTIS AG 269
  - 16.1.4.1 Business overview 269
  - 16.1.4.2 Products offered 271
  - 16.1.4.3 Recent developments 271
    - 16.1.4.3.1 Product approvals 271
    - 16.1.4.3.2 Other developments 272
  - 16.1.4.4 MnM view 272
    - 16.1.4.4.1 Key strengths 272
    - 16.1.4.4.2 Strategic choices 272
    - 16.1.4.4.3 Weaknesses & competitive threats 272
- 16.1.5 AUTOLUS THERAPEUTICS 273
  - 16.1.5.1 Business overview 273
  - 16.1.5.2 Products offered 273
  - 16.1.5.3 Recent developments 274
    - 16.1.5.3.1 Product approvals 274
    - 16.1.5.3.2 Deals 274
  - 16.1.5.4 MnM view 274
    - 16.1.5.4.1 Key strengths 274
    - 16.1.5.4.2 Strategic choices 275
    - 16.1.5.4.3 Weaknesses & competitive threats 275
- 16.1.6 JW (CAYMAN) THERAPEUTICS CO., LTD. 276
  - 16.1.6.1 Business overview 276
  - 16.1.6.2 Products offered 277
  - 16.1.6.3 Recent developments 277
    - 16.1.6.3.1 Product approvals 277
    - 16.1.6.3.2 Deals 278
- 16.1.7 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT) 279
  - 16.1.7.1 Business overview 279
  - 16.1.7.2 Products offered 279
  - 16.1.7.3 Recent developments 280
    - 16.1.7.3.1 Deals 280
    - 16.1.7.3.2 Other developments 281
- 16.1.8 CARSGEN THERAPEUTICS HOLDINGS LIMITED 282

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

16.1.8.1	Business overview	282
16.1.8.2	Products offered	283
16.1.8.3	Recent developments	284
16.1.8.3.1	Product approvals	284
16.1.8.3.2	Deals	285
16.1.8.3.3	Expansions	285
16.1.9	IASO BIOTHERAPEUTICS	286
16.1.9.1	Business overview	286
16.1.9.2	Products offered	286
16.1.9.3	Recent developments	287
16.1.9.3.1	Product approvals	287
16.1.9.3.2	Deals	287
16.1.10	IMMUNEEL THERAPEUTICS	289
16.1.10.1	Business overview	289
16.1.10.2	Products offered	289
16.1.10.3	Recent developments	290
16.1.10.3.1	Product launches	290
16.2	OTHER PLAYERS	290
16.2.1	WUGEN	290
16.2.2	CARTESIAN THERAPEUTICS, INC.	291
16.2.3	ALLOGENE THERAPEUTICS	292
16.2.4	LYELL IMMUNOPHARMA, INC.	293
16.2.5	KYVERNA THERAPEUTICS, INC.	293
16.2.6	CELLICTIS SA	294
16.2.7	BRAINCHILD BIO	294
16.2.8	ATARA BIOTHERAPEUTICS, INC.	295
16.2.9	CARIBOU BIOSCIENCES	295
16.2.10	ARCELLX	296
16.2.11	CRISPR THERAPEUTICS	297
16.2.12	POSEIDA THERAPEUTICS	298
16.2.13	CABALETTA BIO	298
17	RESEARCH METHODOLOGY	299
17.1	RESEARCH DATA	299
17.1.1	SECONDARY DATA	300
17.1.1.1	Objectives of secondary research	300
17.1.2	PRIMARY DATA	301
17.1.2.1	Breakdown of primaries	301
17.1.2.2	Objectives of primary research	302
?		
17.2	MARKET SIZE ESTIMATION	302
17.2.1	BOTTOM-UP APPROACH	303
17.2.2	INSIGHTS FROM PRIMARY EXPERTS	305
17.2.3	SEGMENTAL MARKET SIZE ESTIMATION	306
17.3	GROWTH RATE ASSUMPTIONS	307
17.3.1	CAGR PROJECTIONS	307
17.3.2	IMPACT OF SUPPLY- AND DEMAND-SIDE FACTORS	308
17.4	DATA TRIANGULATION	308

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

17.5	RESEARCH LIMITATIONS	309
17.6	STUDY ASSUMPTIONS	310
17.7	RISK ANALYSIS	311
18	APPENDIX	312
18.1	DISCUSSION GUIDE	312
18.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	316
18.3	CUSTOMIZATION OPTIONS	318
18.4	RELATED REPORTS	318
18.5	AUTHOR DETAILS	319

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**CAR T-Cell Therapy Market by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), Region, Competitive Landscape - Global Forecast to 2031**

Market Report | 2026-02-16 | 320 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code\*

Country\*

Date

2026-03-16

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)